Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension
Completed
- Conditions
- Portal HypertensionCirrhosisEsophageal Neoplasms
- Interventions
- Procedure: Endosocpic resection of early esophageal tumor
- Registration Number
- NCT04994548
- Lead Sponsor
- Central Hospital, Nancy, France
- Brief Summary
Cirrhotic patients may be at high risk for esophageal cancer. Endoscopic resection is the standard treatment for superficial tumors. However, cirrhosis might be associated with upper gastrointestinal bleeding, particularly in case of portal hypertension or coagulopathy. This study aims to assess safety, efficacy and methods to prevent potential complications in cirrhosis or portal hypertension context for esophageal endoscopic resection.
This retrospective multicentric French-Belgian study includes all consecutive patients with cirrhosis or portal hypertension who underwent esophageal endoscopic resection from January 2005 to 2021.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 112
Inclusion Criteria
- older than 18 years with cirrhosis or portal hypertension who underwent endoscopic resection of an early esophageal tumor
Exclusion Criteria
- younger than 18
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cirrhotic patients or with portal hypertension Endosocpic resection of early esophageal tumor Patients with early esophageal cancer
- Primary Outcome Measures
Name Time Method technical success of early esophageal cancer resection baseline defined by a complete macroscopic resection
- Secondary Outcome Measures
Name Time Method preemptive methods to the risk of bleeding baseline morbidity post procedure (delayed bleeding, infection, esophageal stenosis, 30-days related liver decompensation, 30-days related mortality) up to 4 weeks adverse events per procedure (immediate bleeding, perforation) baseline Potential risk factors for adverse events baseline